AURA
NASDAQ · Biotechnology
Aura Biosciences Inc
$8.29
-0.61 (-6.85%)
Open$8.86
Previous Close$8.90
Day High$8.96
Day Low$8.12
52W High$9.54
52W Low$4.35
Volume—
Avg Volume1.04M
Market Cap526.44M
P/E Ratio—
EPS$-1.79
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+291.6% upside
Current
$8.29
$8.29
Target
$32.46
$32.46
$26.53
$32.46 avg
$55.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 444.35M | 423.64M | 422.21M |
| Net Income | 17.80M | 13.08M | 16.40M |
| Profit Margin | 4.0% | 3.1% | 3.9% |
| EBITDA | 20.20M | 21.97M | 19.97M |
| Free Cash Flow | 12.95M | 9.01M | 11.94M |
| Rev Growth | +9.8% | +0.1% | +6.7% |
| Debt/Equity | 1.09 | 1.02 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |